<p>Pfizer Inc on Tuesday forecast sales of about $15 billion from the coronavirus vaccine that it is making along with German partner BioNTech and raised its full-year profit forecast.</p>.<p>The company said that it expects total 2021 revenue of between $59.4 billion and $61.4 billion.</p>.<p>The vaccine was among the first to be authorised for emergency use in the United States and several other countries, and analysts have forecast billions in sales.</p>.<p>In the fourth quarter, the vaccine brought in sales of $154 million, below expectations of $462 million, according to consensus estimates compiled by brokerage Mizuho.</p>.<p>The company now expects full-year adjusted earnings of $3.10 to $3.20 per share, up from its prior forecast of $3 to $3.10 per share</p>
<p>Pfizer Inc on Tuesday forecast sales of about $15 billion from the coronavirus vaccine that it is making along with German partner BioNTech and raised its full-year profit forecast.</p>.<p>The company said that it expects total 2021 revenue of between $59.4 billion and $61.4 billion.</p>.<p>The vaccine was among the first to be authorised for emergency use in the United States and several other countries, and analysts have forecast billions in sales.</p>.<p>In the fourth quarter, the vaccine brought in sales of $154 million, below expectations of $462 million, according to consensus estimates compiled by brokerage Mizuho.</p>.<p>The company now expects full-year adjusted earnings of $3.10 to $3.20 per share, up from its prior forecast of $3 to $3.10 per share</p>